Ethicon gets OK for handheld biopsy unit
Ethicon Endo-Surgery has received Food and Drug Administration marketing clearance for a handheld version of its Mammotome minimally invasive breast-biopsy device. The new unit, called Mammotome Hand Held, will be available Sept. 20, according to the
Ethicon Endo-Surgery has received Food and Drug Administration marketing clearance for a handheld version of its Mammotome minimally invasive breast-biopsy device. The new unit, called Mammotome Hand Held, will be available Sept. 20, according to the Cincinnati-based division of Johnson & Johnson. Ethicon expects Mammotome Hand Held will be employed in physicians offices, breast care centers, and hospitals. Using ultrasound guidance, Mammotome Hand Held vacuums out suspicious tissue for examination, according to the company. The original table-mounted Mammotome has been available in the U.S. since 1995 and has been used for more than 375,000 breast biopsies.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
